January 2019, Volume 5, Issue 1

January 2019

Volume 5, Issue 1

This issue features a look at how hematologists are using social media, the connection between red cell disorders and malaria, and more.

Table of Contents

January 2019 Issue

Alice Ma, MD

Rituals of the Season

Tuesday, January 1st, 2019
I’ll never forget my first American Society of Hematology (ASH) annual meeting. I was a second-year fellow and a novice at “ASHing.” My mentors had...

January 2019 Issue

Remembering Brian P. Sorrentino, NIH Awards Washington University Leukemia Program, and more

Tuesday, January 1st, 2019
Remembering Brian P. Sorrentino (1958-2018) Brian P. Sorrentino, MD, a gene-therapy researcher specializing in the treatment of blood and immune cell disorders, passed away...

ASH Recognizes Choosing Wisely Champions, Scholar Award Winners, and more

Tuesday, January 1st, 2019
Recognizing Champions of Waste Reduction ASH recognized three Choosing Wisely® Champions during the 2018 annual meeting in San Diego. Choosing Wisely, an initiative of the American...

January 2019 Issue

Welcome to the Digital World

Tuesday, January 1st, 2019
Over the past two decades, social media has become an integral part of everyday lives, with millions of people using it as an avenue...

Pulling Back the Curtain: Ifeyinwa (Ify) Osunkwo, MD, MPH

Tuesday, January 1st, 2019
In this edition, Ify Osunkwo, MD, MPH, talks about her childhood in the Bronx and Nigeria, growing up with four sisters, and the friendship...

Malaria and Thalassemia in the Mediterranean Basin

Tuesday, January 1st, 2019
In 1949, British scientist John Burdon Sanderson Haldane made a novel connection between red cell disorders and malaria: The genetic mutations that lead to...

January 2019 Issue

Treatment options for a young woman with stage 2a Hodgkin lymphoma and fertility concerns

Tuesday, January 1st, 2019
This month, David Straus, MD, discusses treatment options for a young woman with stage 2a Hodgkin lymphoma and fertility concerns. And don't forget to check...

January 2019 Issue

WIB_icon

Duvelisib Bests Ofatumumab in Relapsed and Refractory CLL/SLL

Tuesday, January 1st, 2019
In the phase III DUO trial, treatment with the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib improved progression-free survival (PFS) and overall response, compared...

Restrictive Transfusion Therapy Safe for Cardiac Surgery Patients

Tuesday, January 1st, 2019
Setting higher hemoglobin (Hb) thresholds for red-cell transfusion therapy in patients undergoing cardiac surgery with a moderate to high risk of death was noninferior...

Weighing Conditioning Regimens for Patients With CML Undergoing Transplant

Tuesday, January 1st, 2019
Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...

CMS Finalizes Physician Fee Schedule for 2019

Tuesday, January 1st, 2019
The Centers for Medicare and Medicaid Services (CMS) released its final changes to the Medicare Physician Fee Schedule and the Quality Payment Program for...

FDA Approves Elotuzumab-Based Triplet Regimen for Myeloma

Tuesday, January 1st, 2019
The FDA approved the combination of elotuzumab plus pomalidomide and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (MM)...

FDA Issues Draft Guidance on MRD in Clinical Trials

Tuesday, January 1st, 2019
To make drug development and evaluation more efficient, the U.S. Food and Drug Administration (FDA) issued draft guidance on the use of minimal residual...

FDA Expands Brentuximab Vedotin’s Indication

Tuesday, January 1st, 2019
Brentuximab vedotin has been approved in combination with chemotherapy for the firstline treatment of adult patients with certain peripheral T-cell lymphomas (PTCLs). The FDA granted...

January 2019 Issue

Rivaroxaban Reduces Thrombotic Risk in Patients Undergoing Cancer Treatment

Tuesday, January 1st, 2019
Primary prevention with the direct oral anticoagulant (DOAC) rivaroxaban reduced venous thromboembolism (VTE) and VTE-related mortality in patients with cancer, according to results from...

New Sickle Cell Disease Screening Test Is Highly Accurate – and Inexpensive

Tuesday, January 1st, 2019
Editor's note: On March 11, 2019, the editors of Blood retracted this abstract, after a co-author stated it was submitted without his consent. In a population of...

Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL

Tuesday, January 1st, 2019
In patients with previously untreated chronic lymphocytic leukemia (CLL), treatment with an ibrutinib-based therapy improved progression-free survival (PFS) and overall survival (OS), compared with...

Is Daratumumab Plus Lenalidomide-Dexamethasone a New Standard for Transplant-Ineligible Myeloma?

Tuesday, January 1st, 2019
Adding daratumumab to standard combination of lenalidomide and dexamethasone (Rd) reduced the risk of disease progression and death by 44 percent in patients with...

New Tool Provides Simple Approach to Interrupting Direct Oral Anticoagulants for Surgery

Tuesday, January 1st, 2019
Researchers have developed a “simple, standardized, easy-to-use” strategy to guide decisions about interrupting direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) scheduled...

SHARE